S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
Check Out This 6-Year Win Streak (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Check Out This 6-Year Win Streak (Ad)pixel
DOW New Hghs Coming Sooner Than Later
Why did Sarepta Therapeutics Stock Plummet?
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
Check Out This 6-Year Win Streak (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Check Out This 6-Year Win Streak (Ad)pixel
DOW New Hghs Coming Sooner Than Later
Why did Sarepta Therapeutics Stock Plummet?
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
Check Out This 6-Year Win Streak (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Check Out This 6-Year Win Streak (Ad)pixel
DOW New Hghs Coming Sooner Than Later
Why did Sarepta Therapeutics Stock Plummet?
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
Check Out This 6-Year Win Streak (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Check Out This 6-Year Win Streak (Ad)pixel
DOW New Hghs Coming Sooner Than Later
Why did Sarepta Therapeutics Stock Plummet?
NASDAQ:CLVS

Clovis Oncology - CLVS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$0.08
$0.10
50-Day Range
$0.08
$1.09
52-Week Range
$0.08
$3.32
Volume
1.16 million shs
Average Volume
8.88 million shs
Market Capitalization
$11.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CLVS stock logo

About Clovis Oncology (NASDAQ:CLVS) Stock

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Stock News Headlines

Analysts Holding As Pfizer Waits On Two Phase 3 Studies (CLVS)
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
CLVS.O
CLVSQ Clovis Oncology, Inc.
Clovis Oncology
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Boulder drugmaker Clovis Oncology files for bankruptcy
Cancer Focused Clovis Oncology Files For Bankruptcy
U.S. drugmaker Clovis files for Chapter 11 bankruptcy
See More Headlines
Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Company Calendar

Last Earnings
11/03/2021
Today
3/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CLVS
CUSIP
18946410
Employees
N/A
Year Founded
2009

Profitability

Net Income
$-264,520,000.00
Net Margins
-189.37%
Pretax Margin
-189.68%

Debt

Sales & Book Value

Annual Sales
$148.76 million
Book Value
($2.15) per share

Miscellaneous

Free Float
138,577,000
Market Cap
$11.60 million
Optionable
Optionable
Beta
0.24

Social Links


Key Executives

  • Mr. Patrick J. Mahaffy MA (Age 55)
    Co-Founder, Chief Exec. Officer, Pres and Exec. Director
  • Dr. Gillian C. Ivers-Read BSc (Age 64)
    Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations
  • Mr. Daniel W. Muehl CPA (Age 54)
    Sr. VP of Fin. and Principal Financial & Accounting Officer
  • Dr. Lindsey Rolfe BSc (Age 50)
    MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance
  • Mr. Corwin Dale Hooks (Age 51)
    Chief Commercial Officer and Sr. VP













CLVS Stock - Frequently Asked Questions

Should I buy or sell Clovis Oncology stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CLVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View CLVS analyst ratings
or view top-rated stocks.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company earned $37.92 million during the quarter, compared to analyst estimates of $38.73 million. During the same period last year, the company earned ($0.89) EPS.

What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.00%), Aristeia Capital LLC (0.00%), Susquehanna International Group LLP (0.00%), Cutler Group LLC CA (0.00%), Bank of Montreal Can (0.00%) and Wolverine Asset Management LLC (0.00%). Insiders that own company stock include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, Thomas C Harding and Thomas C Harding.
View institutional ownership trends
.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $0.08.

How much money does Clovis Oncology make?

Clovis Oncology (NASDAQ:CLVS) has a market capitalization of $11.60 million and generates $148.76 million in revenue each year. The biopharmaceutical company earns $-264,520,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The official website for the company is www.clovisoncology.com. The biopharmaceutical company can be reached via phone at 303-625-5000, via email at bburkart@clovisoncology.com, or via fax at 303-245-0360.

This page (NASDAQ:CLVS) was last updated on 3/22/2023 by MarketBeat.com Staff